gip/glp-1 agonist Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP-1 receptor agonists and GLP-1 and glucose-dependent insulinotropic π§π΅π² ππ³π³π²π°π πΌπ³ πππ£-π π₯π²π°π²π½ππΌπΏ
Description
GLP-1R Agonist Therapy for Diabetes: Benefits and Potential Risks
Nissen expects tirzepatide to soon join the pure GLP-1 RAs with an FDA-approved indication for weight loss in addition to diabetes, although it may meet the same payer reluctance around reimbursement for weight loss that the pure GLP-1 RAs have

Some case reports show that GLP-1RA treatment initiation in patients leads to worsened Pso lesions, possibly because the drug triggers immune dysregulation, which results in increased pro-inflammatory pathways [19,65]

[DOI] [PMC free article] [PubMed] [Google Scholar] 159.Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC